Tuberculosis (TB) is still the number one cause of death due to an infectious disease.
Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB …

Introduction: Tuberculosis (TB) remains the leading cause of death from a curable infectious
disease; drug-resistant TB threatens to dismantle all prior gains in global control. Suboptimal …

For rapid anti-tuberculosis (TB) drug development in vitro pharmacokinetic/
pharmacodynamic (PK/PD) models are useful in evaluating the direct interaction between …

There has been an increased interest in pharmacokinetics and pharmacodynamics (PKPD)
of anti-tuberculosis drugs. A better understanding of the relationship between drug …

Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science and clinical trial
simulations have not been adequately applied to the design of doses and dose schedules of …

Background Tuberculosis remains the major public health problem besides tremendous
efforts to combat it. Most tuberculosis patients are treated with a standard dose of first-line …

Tuberculosis (TB) kills more people than any other infectious disease. Challenges for
developing better treatments include the complex pathology due to within-host immune …

Introduction Tuberculosis (TB) remains one of the world's deadliest communicable diseases.
Although cure rates of the standard four-drug (rifampicin, isoniazid, pyrazinamide …

Application of clinical pharmacology best practices is essential to the efficient and rational
development of drugs. In general, knowledge gained about exposure–response …

Standard treatment for active tuberculosis (TB) requires drug treatment with at least four
drugs over six months. Shorter-duration therapy would mean less need for strict adherence …